{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:37:29Z","timestamp":1790062649643,"version":"4.0.1"},"publisher-location":"Chichester, UK","reference-count":131,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd002309.pub4","type":"reference-entry","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T09:01:51Z","timestamp":1383555711000},"source":"Crossref","is-referenced-by-count":22,"title":["Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease"],"prefix":"10.1002","author":[{"given":"Jimmy","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillippa","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,11,4]]},"reference":[{"issue":"5 Suppl","key":"10.1002\/14651858.CD002309.pub4-BIB1|cit1","first-page":"A771","article-title":"Cilomilast (Ariflo) a potent selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: Results of a 6 month trial","volume":"163","author":"Edelson","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD002309.pub4-BIB2|cit2","first-page":"A277","article-title":"Cilomilast (Ariflo) improves health status in patients with COPD: Results of a 6-month trial","volume":"163","author":"Edelson","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub4-BIB3|cit3","unstructured":"GSK CTR-039 A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg twice daily) in patients with chronic obstructive pulmonary disease (207499\/039) http:\/\/www.gsk-clinicalstudyregister.com\/result_detail.jsp?protocolId=207499%2f039&studyId=42B8787E-719D-4A66-8180-A7643F656A2A&compound=cilomilast"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub4-BIB4|cit4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.129.1.56","article-title":"Cilomilast for COPD: Results of a 6-month, placebo controlled study of a potent, selective inhibitor of phosphodiesterase 4","volume":"129","author":"Rennard","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub4-BIB5|cit5","unstructured":"GSK CTR-042 A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg twice daily) in patients with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24046.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB6|cit6","unstructured":"GSK CTR-076 A 12-week, multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the anti-inflammatory activity of SB207499 15 mg twice daily in patients with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24047.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB7|cit7","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1164\/rccm.200212-1490OC","article-title":"Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease","volume":"168","author":"Gamble","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub4-BIB8|cit8","unstructured":"GSK CTR-091 A randomized, 24-week, double-blind, placebo-controlled, parallel-group study followed by a 2-week, randomized, double-blind, run-out phase to evaluate the efficacy, safety, tolerability and discontinuation of SB207499 (15 mg twice daily) in patients with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24048.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB9|cit9","unstructured":"GSK CTR-657. A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg BID) in patients with Chronic Obstructive Pulmonary Disease (COPD) http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/20593.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB10|cit10","unstructured":"GSK CTR-110 A 12-week, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the anti-inflammatory activity of cilomilast 15 mg twice daily in patients with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24049.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB11|cit11","unstructured":"GSK CTR-111 A 12-week, randomized, double-blind, placebo-controlled, parallel-group study to investigate the effect of cilomilast (15 mg twice daily) on trapped gas volume in patients with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24050.pdf"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD002309.pub4-BIB12|cit12","first-page":"A226","article-title":"Effect of cilomilast (Ariflo) on trapped gas volume and indices of hyperinflation in patients with chronic obstructive pulmonary disease","volume":"165","author":"Zamel","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub4-BIB13|cit13","unstructured":"GSK CTR-121 A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg BID) in patients with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24042.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB14|cit14","unstructured":"GSK CTR-156 A randomized, 24-week, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of cilomilast (15 mg BID) in patients with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24051.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB15|cit15","unstructured":"GSK CTR-157 A randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of oral cilomilast (15 mg bd) when given as maintenance treatment for 12 months to subjects with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24053.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB16|cit16","unstructured":"GSK CTR-168 A randomized, 12-week, double-blind, placebo-controlled, parallel-group study to evaluate the safety and tolerability of cilomilast 15 mg twice daily in patients with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24054.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB18|cit17","series-title":"Assessment of cardiac events via 24-hour electrocardiographic (Holter) monitoring with cilomilast in chronic obstructive pulmonary disease [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle","first-page":"Poster D86, A03","author":"Reisner","year":"2003"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD002309.pub4-BIB17|cit18","first-page":"Abstract No: P5","article-title":"Assessment of cardiac events via 24-hour electrocardiographic (Holter) monitoring with cilomilast in chronic obstructive pulmonary disease","volume":"22","author":"Reisner","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub4-BIB19|cit19","unstructured":"GSK CTR-180. An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with cilomilast to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise), as well as related exertional dyspnea and exercise performance, in hyperinflated patients with stable COPD http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24052.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB20|cit20","unstructured":"GSK CTR-181 A 13-week randomised, double-blind, parallel group, multicentre study to compare the bronchial anti-inflammatory activity of oral cilomilast (15 mg bd) with placebo twice daily in subjects with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24055.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB21|cit21","series-title":"SB 207499, a second generation, oral PDE4 inhibitor, improves health status in patients with COPD. European Respiratory Society Annual Congress; 1999; Spain","first-page":"P2237","author":"Compton","year":"1999"},{"issue":"9278","key":"10.1002\/14651858.CD002309.pub4-BIB22|cit22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(01)05481-2","article-title":"Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study","volume":"358","author":"Compton","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002309.pub4-BIB23|cit23","unstructured":"Durmowicz AG Cross discipline team leader review Centre for drug evaluation and research"},{"key":"10.1002\/14651858.CD002309.pub4-BIB24|cit24","series-title":"Roflumilast, a new, orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; 2002 14-18 Sep; Stockholm","first-page":"Abstract no: 23","author":"Bredenbroker","year":"2002"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD002309.pub4-BIB25|cit25","first-page":"A595","article-title":"Safety of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in patients with COPD","volume":"165","author":"Bredenbroker","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub4-BIB27|cit26","series-title":"Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease [Abstract]. European Respiratory Society Annual Congress; 2002 Sep 14-17; Stockholm","first-page":"Abstract no: P1","author":"Leichtl","year":"2002"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD002309.pub4-BIB26|cit27","first-page":"A229","article-title":"Efficacy of once-daily roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease","volume":"165","author":"Leichtl","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub4-BIB28|cit28","series-title":"The effect of roflumilast treatment and subsequent withdrawal in patients with COPD. American Thoracic Society International Conference; 2005 May 20-25; San Diego","first-page":"Poster 323","author":"Boszormenyi-Nagy","year":"2005"},{"key":"10.1002\/14651858.CD002309.pub4-BIB29|cit29","series-title":"Onset of action and effect of withdrawal of roflumilast in COPD [Abstract]. European Respiratory Society Annual Congress; 2011 Sep 24-28; Amsterdam","first-page":"147s [P863]","author":"Rabe","year":"2011"},{"key":"10.1002\/14651858.CD002309.pub4-BIB30|cit30","series-title":"Centre for drug evaluation and research","article-title":"Clinical pharmacology and biopharmaceutics review(s)","author":"Ping"},{"key":"10.1002\/14651858.CD002309.pub4-BIB31|cit31","series-title":"Centre for drug evaluation and research","article-title":"Clinical pharmacology and biopharmaceutics review(s)","author":"Ping"},{"key":"10.1002\/14651858.CD002309.pub4-BIB32|cit32","series-title":"Safety profile of roflumilast, a novel, selective phosphodiesterase 4 inhibitor, in patients with moderate to severe COPD [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando","first-page":"C43;Poster F17","author":"Bateman","year":"2004"},{"key":"10.1002\/14651858.CD002309.pub4-BIB33|cit33","series-title":"Roflumilast, a novel selective phosphodiesterase 4 inhibitor, improves quality of life and lowers exacerbation rate in patients with moderate to severe COPD [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando","first-page":"C44;Poster J58","author":"O'Donnell"},{"issue":"Suppl 48","key":"10.1002\/14651858.CD002309.pub4-BIB34|cit34","first-page":"21s","article-title":"Roflumilast an oral once daily PDE4 inhibitor improves lung function and reduces exacerbation rates in patients with COPD [Abstract]","volume":"24","author":"Rabe","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"9485","key":"10.1002\/14651858.CD002309.pub4-BIB35|cit35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(05)67100-0","article-title":"Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial","volume":"36","author":"Rabe","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002309.pub4-BIB36|cit36","series-title":"Roflumilast, a novel, selective phosphodiesterase 4 inhibitor, improves lung function in patients with moderate to severe COPD [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando","first-page":"C22;Poster 509","author":"Rabe","year":"2004"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD002309.pub4-BIB37|cit37","doi-asserted-by":"crossref","first-page":"709S","DOI":"10.1378\/chest.126.4_MeetingAbstracts.709S-a","article-title":"Roflumilast improves lung function and quality of life in chronic obstructive pulmonary disease [Abstract]","volume":"126","author":"Rabe","year":"2004","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub4-BIB38|cit38","unstructured":"Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217\/M2-110) http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00062582"},{"key":"10.1002\/14651858.CD002309.pub4-BIB39|cit39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1465-9921-12-18","article-title":"Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD","volume":"12","author":"Rennard","year":"2011","journal-title":"Respiratory Research"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub4-BIB40|cit40","first-page":"67","article-title":"Efficacy of roflumilast when used with concomitant inhaled corticosteroids from the OPUS\/RATIO studies [Abstracts]","volume":"82","author":"Rusch","year":"2011","journal-title":"Respiration"},{"key":"10.1002\/14651858.CD002309.pub4-BIB41|cit41","doi-asserted-by":"crossref","unstructured":"Rennard SI Calverley PM Goehring UM Bredenbroker D Martinez FJ Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD Respiratory Research 2011 18","DOI":"10.1186\/1465-9921-12-18"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub4-BIB42|cit42","first-page":"67","article-title":"Efficacy of roflumilast when used with concomitant inhaled corticosteroids from the OPUS\/RATIO studies [Abstracts]","volume":"82","author":"Rusch","year":"2011","journal-title":"Respiration"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002309.pub4-BIB43|cit43","first-page":"ii42","article-title":"Effect of roflumilast on lung function and exacerbations in patients with chronic obstructive pulmonary disease: results of a one year study [Abstract]","volume":"2","author":"Calverley","year":"2005","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub4-BIB44|cit44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1164\/rccm.200610-1563OC","article-title":"Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease","volume":"176","author":"Calverley","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub4-BIB45|cit45","series-title":"Effect of roflumilast on lung function: a 1-year study in patients with severe to very severe COPD [Abstract]. Proceedings of the American Thoracic Society; 2006 May 19-24; San Diego","first-page":"A725","author":"Calverley","year":"2006"},{"key":"10.1002\/14651858.CD002309.pub4-BIB46|cit46","series-title":"Effect of roflumilast on exacerbations: a 1-year study in patients with severe to very severe COPD [Abstract]. American Thoracic Society Conference; 2006 May 19-24; San Diego","first-page":"A841;Poster 615","author":"Fabbri","year":"2006"},{"key":"10.1002\/14651858.CD002309.pub4-BIB47|cit47","series-title":"American Thoracic Society Conference; 2006 May 19-24; San Diego","first-page":"A850","article-title":"Effect of roflumilast on quality of life: a 1-year study in patients with severe to very severe COPD","author":"Mclvor","year":"2006"},{"key":"10.1002\/14651858.CD002309.pub4-BIB48|cit48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1465-9921-12-18","article-title":"Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD","volume":"12","author":"Rennard","year":"2011","journal-title":"Respiratory Research"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub4-BIB49|cit49","first-page":"67","article-title":"Efficacy of roflumilast when used with concomitant inhaled corticosteroids from the OPUS\/RATIO studies [Abstracts]","volume":"82","author":"Rusch","year":"2011","journal-title":"Respiration"},{"issue":"Suppl 51","key":"10.1002\/14651858.CD002309.pub4-BIB50|cit50","first-page":"194s, P1188","article-title":"The 1-year cost effectiveness of roflumilast for the treatment of severe to very severe COPD patients [Abstract]","volume":"30","author":"Rutten-van Molken","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD002309.pub4-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1183\/09031936.00096511","article-title":"Physiological effects of roflumilast at rest and during exercise in COPD","volume":"39","author":"O'Donnell","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub4-BIB52|cit52","series-title":"Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial [Abstract]. European Respiratory Society Annual Congress; 2011 Sep 24-28; Amsterdam","first-page":"600s [P3364]","author":"Hui","year":"2011"},{"issue":"8","key":"10.1002\/14651858.CD002309.pub4-BIB53|cit53","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1440-1843.2011.02038.x","article-title":"Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial","volume":"16","author":"Lee","year":"2011","journal-title":"Respirology (Carlton, Vic.)"},{"key":"10.1002\/14651858.CD002309.pub4-BIB54|cit54","unstructured":"The HERO-study: Effects of Roflumilast in Patients With COPD (Chronic Obstructive Pulmonary Disease) (BY217\/M2-121) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00108823?term=roflumilast+copd&rank=21"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub4-BIB55|cit55","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB56|cit56","first-page":"3S","article-title":"Efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast in patients with symptomatic chronic obstructive pulmonary disease in the M2-124 study","volume":"136","author":"Martinez","year":"2009","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB57|cit57","first-page":"119","article-title":"Roflumilast in combination with long-acting bronchodilators","volume":"138","author":"Nowak","year":"2013","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD002309.pub4-BIB58|cit58","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/09031936.00178710","article-title":"Roflumilast with long-acting beta2-agonists for COPD: Influence of exacerbation history","volume":"38","author":"Bateman","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub4-BIB59|cit59","series-title":"Efficacy of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna","first-page":"1629","author":"Calverley","year":"2009"},{"key":"10.1002\/14651858.CD002309.pub4-BIB60|cit60","series-title":"Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD [Abstract]. European Respiratory Society Annual Congress; 2011 Sep 24-28; Amsterdam","first-page":"19s [P248]","author":"Calverley","year":"2011"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub4-BIB61|cit61","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"issue":"9747","key":"10.1002\/14651858.CD002309.pub4-BIB62|cit62","first-page":"1146","article-title":"Erratum: Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomised clinical trials (The Lancet (2009) 374 (685-694))","volume":"376","author":"Calverley","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub4-BIB63|cit63","first-page":"67","article-title":"Efficacy of roflumilast in patients receiving concomitant treatments for chronic obstructive pulmonary disease over 12 months [Abstract]","volume":"82","author":"Gooss","year":"2011","journal-title":"Respiration"},{"key":"10.1002\/14651858.CD002309.pub4-BIB64|cit64","first-page":"A4435","article-title":"Efficacy of roflumilast in patients receiving concomitant treatments for chronic obstructive pulmonary disease over 12 months [Abstract]","volume":"181(Meeting Abs","author":"Hanania","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub4-BIB65|cit65","first-page":"A13 [50]","article-title":"Efficacy of roflumilast in patients with symptomatic chronic obstructive pulmonary disease (COPD) receiving concomitant bronchodilator treatments [Abstract]","volume":"19","author":"Kaplan","year":"2010","journal-title":"Primary Care Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub4-BIB66|cit66","series-title":"Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna","first-page":"1630","author":"Martinez","year":"2009"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB67|cit67","first-page":"119","article-title":"Roflumilast in combination with long-acting bronchodilators","volume":"138","author":"Nowak","year":"2013","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB68|cit68","first-page":"93S","article-title":"Efficacy and safety of the phosphodiesterase 4 inhibitor roflumilast in patients with symptomatic chronic obstructive pulmonary disease in the M2-125 study","volume":"136","author":"Andrew","year":"2009","journal-title":"Chest"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub4-BIB69|cit69","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB70|cit70","first-page":"119","article-title":"Roflumilast in combination with long-acting bronchodilators","volume":"138","author":"Nowak","year":"2013","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB71|cit71","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1378\/chest.136.4_MeetingAbstracts.3S-g","article-title":"Additional clinical benefit in patients with chronic obstructive pulmonary disease treated with roflumilast and salmeterol","volume":"136","author":"Chapman","year":"2009","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub4-BIB72|cit72","first-page":"A12 [44]","article-title":"Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease (COPD) concomitantly treated with tiotropium or salmeterol [Abstract]","volume":"19","author":"Chapman","year":"2010","journal-title":"Primary Care Respiratory Journal"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub4-BIB73|cit73","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002309.pub4-BIB74|cit74","series-title":"The PDE4 inhibitor roflumilast provides additional clinical benefit in COPD patients receiving salmeterol [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna","first-page":"1627","author":"Izquierdo","year":"2009"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB75|cit75","doi-asserted-by":"crossref","first-page":"467A","DOI":"10.1378\/chest.10507","article-title":"Benefit of roflumilast therapy added to salmeterol in patients with varying chronic obstructive pulmonary disease severity [Abstract]","volume":"138","author":"Martinez","year":"2010","journal-title":"Chest"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002309.pub4-BIB76|cit76","first-page":"S85","article-title":"Effect of roflumilast treatment on dyspnea in patients with chronic obstructive pulmonary disease [Abstract]","volume":"7","author":"Sun","year":"2012","journal-title":"Journal of Hospital Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002309.pub4-BIB77|cit77","first-page":"S81","article-title":"Effect of roflumilast treatment on health related quality of life in patients with chronic obstructive pulmonary disease [Abstract]","volume":"7","author":"Sun","year":"2012","journal-title":"Journal of Hospital Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub4-BIB78|cit78","first-page":"A12 [44]","article-title":"Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease (COPD) concomitantly treated with tiotropium or salmeterol [Abstract]","volume":"19","author":"Chapman","year":"2010","journal-title":"Primary Care Respiratory Journal"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub4-BIB79|cit79","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB80|cit80","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1378\/chest.136.4_MeetingAbstracts.3S-g","article-title":"Improvements in breathlessness in patients with chronic obstructive pulmonary disease treated with roflumilast and tiotropium","volume":"136","author":"Paggiaro","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub4-BIB81|cit81","series-title":"Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium [Abstract]. European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna","first-page":"1628","author":"Rabe","year":"2009"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD002309.pub4-BIB82|cit82","first-page":"A2261","article-title":"Effect of roflumilast treatment added to tiotropium on dyspnea in patients with chronic obstructive pulmonary disease [Abstract]","volume":"185","author":"Rennard","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub4-BIB83|cit83","first-page":"A4473","article-title":"Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease [Abstract]","volume":"181(Meeting Abs","author":"Wouters","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB84|cit84","doi-asserted-by":"crossref","first-page":"170S","DOI":"10.1378\/chest.124.4_MeetingAbstracts.170S-b","article-title":"Effect of cilomilast on quality of life improvement\/deterioration and non-drug costs in patients with chronic obstructive pulmonary disease","volume":"124","author":"Borker","year":"2003","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB85|cit85","doi-asserted-by":"crossref","first-page":"171S","DOI":"10.1378\/chest.124.4_MeetingAbstracts.171S","article-title":"Cardiovascular safety of cilomilast in patients with chronic obstructive pulmonary disease","volume":"124","author":"Ferguson","year":"2003","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB86|cit86","doi-asserted-by":"crossref","first-page":"129S","DOI":"10.1378\/chest.124.4_MeetingAbstracts.129S","article-title":"Effect of cilomilast on chronic obstructive pulmonary disease patients with impaired quality of life","volume":"124","author":"Fischer","year":"2003","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub4-BIB87|cit87","first-page":"1:35s","article-title":"First dose bronchodilating effect of phosphodiesterase- 4 (PDE-4) inhibition by cilomilast (Ariflo) with or without co-administration of salbutamol and\/or ipratropium in COPD patients","volume":"18(Suppl 33)","author":"Grootendorst","year":"2001","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub4-BIB88|cit88","first-page":"A226","article-title":"Effect of a PDE4 inhibitor (Bay 19-8004) on FEV1 and airway inflammation in patients with COPD","volume":"165(8 Suppl)","author":"Grootendorst","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub4-BIB89|cit89","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1094-5539(02)00172-4","article-title":"Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?","volume":"16","author":"Grootendorst","year":"2003","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"12","key":"10.1002\/14651858.CD002309.pub4-BIB90|cit90","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/thx.2006.075937","article-title":"Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD","volume":"62","author":"Grootendorst","year":"2007","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002309.pub4-BIB91|cit91","first-page":"A4444","article-title":"A four-week randomized study of the safety and tolerability of the inhaled PDE4 inhibitor GSK256066 in COPD [Abstract]","volume":"181(Meeting Abs","author":"Lazaar","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub4-BIB92|cit92","first-page":"A271","article-title":"COPD exacerbation in a 6-month trial of cilomilast (Ariflo) a potent, selective phosphodiesterase 4 inhibitor","volume":"165(Suppl 8)","author":"Kelsen","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub4-BIB93|cit93","series-title":"Cilomilast is efficacious in chronic obstructive pulmonary disease [Abstract]. American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle","first-page":"A035;Poster D92","author":"Knobil","year":"2003"},{"key":"10.1002\/14651858.CD002309.pub4-BIB94|cit94","first-page":"Abstract No:P53","article-title":"Cilomilast is efficacious in chronic obstructive pulmonary disease [Abstract]","volume":"22(Suppl 45)","author":"Reisner","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub4-BIB95|cit95","first-page":"88s","article-title":"Cilomilast decreases exacerbations and maintains lung function in patients with poorly reversible COPD","volume":"24(Suppl 48)","author":"Lim","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub4-BIB96|cit96","series-title":"The effects of low dose SB207499, a second generation, oral PDE4 inhibitor, in patients with COPD. European Respiratory Society Congress; 1999; Madrid","first-page":"P2236","author":"Nieman","year":"1999"},{"key":"10.1002\/14651858.CD002309.pub4-BIB97|cit97","series-title":"American Thoracic Society International Conference; 2007 May 18-23; San Francisco","first-page":"Poster C31","article-title":"Gradual dose escalation of QAK423, a novel PDE4 inhibitor, significantly improves the tolerability [Abstract]","author":"Pascoe","year":"2007"},{"key":"10.1002\/14651858.CD002309.pub4-BIB98|cit98","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1378\/chest.124.4_MeetingAbstracts.127S-c","article-title":"Cilomilast reduces exacerbations in patients with chronic obstructive pulmonary disease","volume":"124","author":"Reisner","year":"2003","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub4-BIB99|cit99","series-title":"The effect of roflumilast treatment on exacerbations in patients with COPD results of a pooled analysis of two 1-year studies [Abstract]. American Thoracic Society International Conference; 2008 May 16-21; Toronto","first-page":"A963","author":"Rennard","year":"2008"},{"key":"10.1002\/14651858.CD002309.pub4-BIB100|cit100","series-title":"Centre for drug evaluation and research","article-title":"Clinical pharmacology and biopharmaceutics review(s)","author":"Ping"},{"key":"10.1002\/14651858.CD002309.pub4-BIB101|cit101","unstructured":"GSK CTR-040 A multicentre, open-label extension study to evaluate the safety, tolerability and efficacy of oral SB-207499 (15 mg twice daily) in patients with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24044.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB102|cit102","unstructured":"GSK CTR-041 A multicenter open-label extension study to evaluate the safety, tolerability and efficacy of oral cilomilast (15 mg twice daily) in patients with chronic obstructive pulmonary disease http:\/\/www.gsk-clinicalstudyregister.com\/files\/pdf\/24045.pdf"},{"key":"10.1002\/14651858.CD002309.pub4-BIB103|cit103","first-page":"A135","article-title":"Improvement in lung residual volume in patients with COPD roles of anti-inflammation activity of cilomilast","volume":"10(Suppl 3)","author":"Song","year":"2005","journal-title":"Respiratory"},{"key":"10.1002\/14651858.CD002309.pub4-BIB104|cit104","first-page":"245s","article-title":"The direct costs of exacerbations in COPD and the effect of cilomilast treatment","volume":"20(Suppl 38)","author":"Spencer","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub4-BIB105|cit105","first-page":"612s [P3598]","article-title":"A 6 week study of the efficacy and safety of UK 500,001 dry powder for inhalation (DPI) in adults with chronic obstructive pulmonary disease [Abstract]","volume":"30(Suppl 51)","author":"Vestbo","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD002309.pub4-BIB106|cit106","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1183\/09031936.00068908","article-title":"A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD","volume":"33","author":"Vestbo","year":"2009","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB107|cit107","doi-asserted-by":"crossref","first-page":"262S","DOI":"10.1378\/chest.128.4.2551","article-title":"Efficacy and anti-inflammation activity of a selective phospodiesterase-4 inhibitor cilomilast in treatment of COPD","volume":"128","author":"Wang","year":"2005","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002309.pub4-BIB109|cit108","unstructured":"Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 \u00b5g Versus Placebo. The REACT Trial http:\/\/clinicaltrials.gov\/show\/NCT01329029"},{"issue":"1","key":"10.1002\/14651858.CD002309.pub4-BIB108|cit109","first-page":"375","article-title":"Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol","volume":"7","author":"Calverley","year":"2012","journal-title":"International Journal of COPD"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD002309.pub4-BIB110|cit110","first-page":"A2946","article-title":"Roflumilast treatment in COPD patients taking a fixed-dose combination of long-acting \u03b22 agonist (LABA) and inhaled corticosteroid (ICS): rationale and design of a prospective randomized controlled trial [Abstract]","volume":"185","author":"Ferguson","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002309.pub4-BIB111|cit111","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.rmed.2004.11.006","article-title":"COPD, a multicomponent disease: implications for management","volume":"99","author":"Agusti","year":"2005","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD002309.pub4-BIB112|cit112","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM200007273430407","article-title":"Medical progress: chronic obstructive pulmonary disease","volume":"343","author":"Barnes","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002309.pub4-BIB113|cit113","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1164\/rccm.200210-1142PP","article-title":"Theophylline: new perspectives for an old drug","volume":"167","author":"Barnes","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002309.pub4-BIB114|cit114","first-page":"334","article-title":"Theophylline in chronic obstructive pulmonary disease: new horizons","volume":"2","author":"Barnes","year":"2005","journal-title":"Proceedings of the American Thoracic Society Congress; 2005 May 20-25; San Diego"},{"key":"10.1002\/14651858.CD002309.pub4-BIB115|cit115","doi-asserted-by":"crossref","first-page":"s252","DOI":"10.1038\/sj.bjp.0706495","article-title":"Phosphodiesterase inhibitors","volume":"147","author":"Boswell-Smith","year":"2006","journal-title":"British Journal of Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD002309.pub4-BIB116|cit116","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002309.pub4-BIB117|cit117","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002309.pub4-BIB118|cit118","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1081\/COPD-200053377","article-title":"Minimal clinically important differences in COPD lung function","volume":"2","author":"Donohue","year":"2005","journal-title":"COPD"},{"issue":"5","key":"10.1002\/14651858.CD002309.pub4-BIB119|cit119","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1067\/mai.2001.119555","article-title":"Cyclic nucleotide phosphodiesterases","volume":"108","author":"Essayan","year":"2001","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"9691","key":"10.1002\/14651858.CD002309.pub4-BIB120|cit120","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002309.pub4-BIB121|cit121","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1164\/rccm.200212-1490OC","article-title":"Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease","volume":"168","author":"Gamble","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002309.pub4-BIB122|cit122","unstructured":"Global Strategy for the Diagnosis Management Prevention of COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 Available from: http:\/\/www.goldcopd.org\/"},{"key":"10.1002\/14651858.CD002309.pub4-BIB123|cit123","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD002309.pub4-BIB124|cit124","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"10.1002\/14651858.CD002309.pub4-BIB125|cit125","volume-title":"Updated projections of global mortality and burden of disease, 2002-2030: data sources, methods and results. Evidence and Information for Policy Working Paper","author":"Mathers","year":"2005"},{"key":"10.1002\/14651858.CD002309.pub4-BIB126|cit126","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"issue":"8","key":"10.1002\/14651858.CD002309.pub4-BIB127|cit127","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub4-BIB128|cit128","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1164\/ajrccm.157.2.9708012","article-title":"Phosphodiesterase isozymes: molecular targets for novel antiasthma agents","volume":"157","author":"Torphy","year":"1998","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002309.pub4-BIB129|cit129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/pupt.1999.0181","article-title":"Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic","volume":"12","author":"Torphy","year":"1999","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD002309.pub4-BIB130|cit130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.rmed.2003.12.012","article-title":"PDE4 inhibitors in COPD--a more selective approach to treatment","volume":"98","author":"Vignola","year":"2004","journal-title":"Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002309.pub4-BIB131|cit131","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1378\/chest.12-2332","article-title":"Cardiovascular safety in patients receiving roflumilast for the treatment of chronic obstructive pulmonary disease","volume":"144","author":"White","year":"2013","journal-title":"Chest"}],"updated-by":[{"DOI":"10.1002\/14651858.cd002309.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T00:00:00Z","timestamp":1505779200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD002309.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:11:42Z","timestamp":1628529102000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002309.pub4"}},"subtitle":[],"editor":[{"given":"Phillippa","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,11,4]]},"references-count":131,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002309.pub4","relation":{},"subject":[],"published":{"date-parts":[[2013,11,4]]}}}